Keeping Abreast of the Facts

There’s growing evidence that nutrition and lifestyle changes can impact prevention, development, progression and survival in breast cancer. Here I share a few references for the studies that underpin my work:

Allen, B.G. et al., 2014. Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism. Redox Biology, 2, pp.963–970.

Ames, B., 2001. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 475(1-2), pp.7-20.

Aragón, F., 2014. Modification in the diet can induce beneficial effects against breast cancer. World Journal of Clinical Oncology, 5(3), p.455. 

Azrad, M., Turgeon, C. & Demark-Wahnefried, W., 2013. Current evidence linking polyunsaturated Fatty acids with cancer risk and progression. Frontiers in Oncology, 3(September), p.224.

Basse, C. and Arock, M., 2015. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. International Journal of Cancer, 137(12), p.2785-2794

Boon, H.S., Olatunde, F. & Zick, S.M., 2007. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC women’s health, 7(1), p.4.

Bozzetti, F. & Zupec-Kania, B., 2016. Toward a cancer-specific diet. Clinical Nutrition, 35(5), pp.1188–1195.

Braakhuis, A., Campion, P. and Bishop, K., 2016. Reducing Breast Cancer Recurrence: The Role of Dietary Polyphenolics. Nutrients, 8(9), p.547.

Branca, J. Pacini, S. Ruggiero, M., 2015. Effects of Pre-surgical Vitamin D Supplementation and Ketogenic Diet in a Patient with Recurrent Breast Cancer. Anticancer Research, 35(10), p.5525-5532.

Bultman, S., 2016. The microbiome and its potential as a cancer preventive intervention. Seminars in Oncology, 43(1), pp.97-106.

Clayton, P. and Rowbotham, J. (2009). How the Mid-Victorians Worked, Ate and Died. International Journal of Environmental Research and Public Health, 6(3), pp.1235-1253.

Cornelius, C. et al., 2013. Stress responses, vitagenes and hormesis as critical determinants in aging and longevity: Mitochondria as a “ chi.” Immunity and Ageing, 10(1), p.15.

Dorff, T., Groshen, S., Garcia, A., Shah, M., Tsao-Wei, D., Pham, H., Cheng, C., Brandhorst, S., Cohen, P., Wei, M., Longo, V. and Quinn, D. (2016). Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer, 16(1).

Grivennikov, S., Greten, F. and Karin, M. (2010). Immunity, Inflammation, and Cancer. Cell, 140(6), pp.883-899.

Gunter, M., Xie, X., Xue, X., Kabat, G., Rohan, T., Wassertheil-Smoller, S., Ho, G., Wylie-Rosett, J., Greco, T., Yu, H., Beasley, J. and Strickler, H. (2015). Breast Cancer Risk in Metabolically Healthy but Overweight Postmenopausal Women. Cancer Research, 75(2), pp.270-274.

Hanahan, D. & Weinberg, R.A., 2011. Hallmarks of cancer: The next generation. Cell, 144(5), pp.646–674.

Holloway, K., Barbieri, A., Malyarchuk, S., Saxena, M., Nedeljkovic-Kurepa, A., Cameron Mehl, M., Wang, A., Gu, X. and Pruitt, K. (2013). SIRT1 Positively Regulates Breast Cancer Associated Human Aromatase (CYP19A1) Expression. Molecular Endocrinology, 27(3), pp.480-490.

Hyde, P., Lustberg, M., Miller, V., LaFountain, R. and Volek, J. (2017). Pleiotropic effects of nutritional ketosis: Conceptual framework for keto-adaptation as a breast cancer therapy. Cancer Treatment and Research Communications, 12, pp.32-39.

İyikesici, M.S. et al., 2017. Efficacy of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy for Stage IV Triple-Negative Breast Cancer. Cureus. 

Kotepui, M., 2016. Diet and risk of breast cancer. Współczesna Onkologia, 1, pp.13-19.

Kumar, P., Barua, C., Sulakhiya, K. and Sharma, R. (2017). Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy. Frontiers in Pharmacology, 8(APR).

Kwa, M. Plottel, CS. Blaser, MJ. Adams, S., 2016. The Intestinal Microbiome and Estrogen Receptor–Positive Female Breast Cancer.  JNCI: Journal of the National Cancer Institute, 108(8), pp.1-10.

Lee, C. & Longo, V.D., 2011. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene, 30(30), pp.3305–3316. 

Longo, V. and Mattson, M., 2014. Fasting: Molecular Mechanisms and Clinical Applications. Cell Metabolism, 19(2), p.181-192

Noakes, T.D. & Windt, J., 2017. Evidence that supports the prescription of low-carbohydrate high-fat diets: A narrative review. British Journal of Sports Medicine, 51(2), pp.133–139.

O’Flanagan, C., Smith, L., McDonell, S. and Hursting, S., 2017. When less may be more: calorie restriction and response to cancer therapy. BMC Medicine, 15(1).

Schwabe, R.F. & Jobin, C., 2013. The microbiome and cancer. Nature reviews. Cancer, 13(11), pp.800–12. 

Seyfried, T. and Shelton, L., 2010. Cancer as a metabolic disease. Nutrition & Metabolism, 7(1), p.7.

Shay, J. and Wright, W. (2007). Tissue Culture as a Hostile Environment: Identifying Conditions for Breast Cancer Progression Studies. Cancer Cell, 12(2), pp.100-101.

Teegarden, D., Romieu, I. and Lelièvre, S. (2012). Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nutrition Research Reviews, 25(01), pp.68-95.

Wang, H., Altemus, J., Niazi, F., Green, H., Calhoun, B., Sturgis, C., Grobmyer, S. and Eng, C., 2017. Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget, 8(50) pp88122-88138.

Wassertheil-Smoller, S., McGinn, A., Budrys, N., Chlebowski, R., Ho, G., Johnson, K., Lane, D., Li, W., Neuhouser, M., Saquib, J., Shikany, J., Song, Y. and Thomson, C. (2013). Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative. Breast Cancer Research and Treatment, 141(3), pp.495-505.

Toledo, E. et al., 2015. Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial. JAMA Internal Medicine, 175(11), p.1.